Interestingly, AYA gliomas had more mutations in ATRX (41.3% vs. 12.5%), a chromatin regulator previously associated with Alternative Lengthening of Telomeres26 (ALT), a telomere maintenance pathway complementary to active telomerase. Here, ATRX is linked to central nervous system cancer.